Skip to main content
SpringerLink
Log in

Tumor cell and circulating markers in melanoma: Diagnosis, prognosis, and management

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

The search is on for biomarkers for use in the diagnosis, staging, prognosis, and management of patients with melanoma. As with many types of cancer, the hematogenous spread of melanoma is a bad prognostic sign, and many groups have attempted to detect circulating melanoma cells in patients with different stages of melanoma. Some studies have used direct extraction of intact tumor cells from the peripheral blood and others the detection of surrogate markers of circulating melanoma cells, such as tyrosinase or MART-1. However, a correlation between the detection of intact melanoma cells in the circulation and prognosis is controversial. Many other biomarkers have also been studied, including lactate dehydrogenase, S100, TA90, and C-reactive protein. Much progress has been made, and preliminary studies have shown promise with many of these markers. Finally, the detection of tumor-specific circulating DNA has shown promise as a prognostic and diagnostic marker of disease in melanoma as well. In this review we examine the most promising biomarkers for use in patients with cutaneous melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Balch CM,Buzaid AC,Soong SJ,et al.:Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3635–3648.

    PubMed  CAS  Google Scholar 

  2. Reintgen D,Cruse CW,Wells K, et al.:The orderly progression of melanoma nodal metastases. Ann Surg 1994, 220:759–767.

    Article  PubMed  CAS  Google Scholar 

  3. Pretlow TP,Bailey JM, Herrera GA, et al.:Culture in soft agar of melanoma cells separated from human peripheral blood. Br J Cancer 1986, 53:411–414.

    PubMed  CAS  Google Scholar 

  4. Ulmer A,Schmidt-Kittler O,Fischer J, et al.:Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin Cancer Res 2004, 10:531–537.

    Article  PubMed  CAS  Google Scholar 

  5. Sarantou T,Chi DD,Garrison DA, et al.:Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 1997, 57:1371–1376.

    PubMed  CAS  Google Scholar 

  6. Goydos JS,Ravikumar TS,Germino FJ, et al.:Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction. J Am Coll Surg 1998, 187:182–188, discussion 188–190.

    Article  PubMed  CAS  Google Scholar 

  7. Goydos JS,Patel KN,Shih WJ, et al.:Patterns of recurrence in patients with melanoma and histologically negative but RT-PCR-positive sentinel lymph nodes. J Am Coll Surg 2003, 196:196–204, discussion 204–195.

    Article  PubMed  Google Scholar 

  8. Starz H,Haas CJ,Schulz GM,Balda BR: Tyrosinase RT-PCR as a supplement to histology for detecting melanoma and nevus cells in paraffin sections of sentinel lymph nodes. Mod Pathol 2003, 16:920–929.

    Article  PubMed  Google Scholar 

  9. Ulrich J,Bonnekoh B,Bockelmann R, et al.:Prognostic significance of detecting micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies: lessons from 322 consecutive melanoma patients. Eur J Cancer 2004, 40:2812–2819. Important large study that summarizes the state of the art of detecting occult melanoma cells in tissues.

    Article  PubMed  CAS  Google Scholar 

  10. Gogas H,Kefala G,Bafaloukos D, et al.:Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br J Cancer 2002, 87:181–186. Good study summarizing the uses of RT-PCR in peripheral blood.

    Article  PubMed  CAS  Google Scholar 

  11. Jin HY,Yamashita T,Minamitsuji Y, et al.:Detection of tyrosinase and tyrosinase-related protein 1 sequences from peripheral blood of melanoma patients using reverse transcriptionpolymerase chain reaction. J Dermatol Sci 2003, 33:169–176.

    Article  PubMed  CAS  Google Scholar 

  12. Mellado B,Gutierrez L,Castel T, et al.:Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res 1999, 5:1843–1848.

    PubMed  CAS  Google Scholar 

  13. Mocellin S,Del Fiore P,Guarnieri L, et al.:Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer 2004, 111:741–745.

    Article  PubMed  CAS  Google Scholar 

  14. Osella-Abate S,Savoia P,Quaglino P, et al.:Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients. Br J Cancer 2003, 89:1457–1462.

    Article  PubMed  CAS  Google Scholar 

  15. Palmieri G,Ascierto PA,Perrone F, et al.:Prognostic value of circulating melanoma cells detected by reverse transcriptasepolymerase chain reaction. J Clin Oncol 2003, 21:767–773.

    Article  PubMed  CAS  Google Scholar 

  16. Palmieri G,Strazzullo M,Ascierto PA, et al.:Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. J Clin Oncol 1999, 17:304–311.

    PubMed  CAS  Google Scholar 

  17. Quaglino P,Savoia P,Osella-Abate S,Bernengo MG: RT-PCR tyrosinase expression in the peripheral blood of melanoma patients. Expert Rev Mol Diagn 2004, 4:727–741.

    Article  PubMed  CAS  Google Scholar 

  18. Ranieri JM,Wagner JD,Wiebke EA, et al.:Lack of prognostic importance of reverse-transcriptase polymerase chain reaction detection of circulating messenger RNA in patients with melanoma. Plast Reconstr Surg 2005, 115:1058–1063.

    Article  PubMed  CAS  Google Scholar 

  19. Voit C,Kron M,Rademaker J, et al.:Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J Clin Oncol 2005, 23:1218–1227.

    Article  PubMed  CAS  Google Scholar 

  20. Smith B,Selby P,Southgate J, et al.:Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991, 338:1227–1229.

    Article  PubMed  CAS  Google Scholar 

  21. Glaser R,Rass K,Seiter S, et al.:Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol 1997, 15:2818–2825. Well-written negative trial that sets out the major roadblocks to RT-PCR studies in the peripheral blood.

    PubMed  CAS  Google Scholar 

  22. Reinhold U,Ludtke-Handjery HC,Schnautz S, et al.:The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 1997, 108:166–169.

    Article  PubMed  CAS  Google Scholar 

  23. Koyanagi K,Kuo C,Nakagawa T, et al.:Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 2005, 51:981–988. Epub 2005 Apr 7.

    Article  PubMed  CAS  Google Scholar 

  24. Max N,Wolf K,Spike B, et al.:Nested quantitative real time PCR for detection of occult tumor cells. Recent Results Cancer Res 2001, 158:25–31.

    PubMed  CAS  Google Scholar 

  25. Reynolds SR,Albrecht J,Shapiro RL, et al.:Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003, 9:1497–1502.

    PubMed  CAS  Google Scholar 

  26. Deichmann M,Benner A,Bock M, et al.:S100-Beta, melanomainhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999, 17:1891–1896.

    PubMed  CAS  Google Scholar 

  27. Eton O,Legha SS,Moon TE, et al.:Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998, 16:1103–1111.

    PubMed  CAS  Google Scholar 

  28. Keilholz U,Conradt C,Legha SS, et al.:Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998, 16:2921–2929.

    PubMed  CAS  Google Scholar 

  29. Wang TS,Johnson TM,Cascade PN, et al.:Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 2004, 51:399–405. Good overview of the use of LDH in following patients with melanoma. Discusses the strengths and weaknesses of this marker well.

    Article  PubMed  Google Scholar 

  30. Deichmann M,Kahle B,Moser K, et al.:Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 2004, 91:699–702. Summarizes in a clear, concise fashion the use of C-reactive protein in following patients with melanoma.

    PubMed  CAS  Google Scholar 

  31. Gaynor R,Irie R,Morton D,Herschman HR: S100 protein is present in cultured human malignant melanomas. Nature 1980, 286:400–401.

    Article  PubMed  CAS  Google Scholar 

  32. Harpio R,Einarsson R: S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 2004, 37:512–518.

    Article  PubMed  CAS  Google Scholar 

  33. Wilder PT,Rustandi RR,Drohat AC,Weber DJ: S100B(betabeta) inhibits the protein kinase C-dependent phosphorylation of a peptide derived from p53 in a Ca2 +-dependent manner. Protein Sci 1998, 7:794–798.

    Article  PubMed  CAS  Google Scholar 

  34. Jury CS,McAllister EJ,MacKie RM: Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 2000, 143:269–274. Excellent study looking at the use of S100 in following patients with melanoma.

    Article  PubMed  CAS  Google Scholar 

  35. Smit LH,Korse CM,Hart AA, et al.:Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 2005, 41:386–392.

    Article  PubMed  CAS  Google Scholar 

  36. Gupta RK,Morton DL: Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated-antigen-specific immune complexes in cancer patients. J Clin Lab Anal 1992, 6:329–336.

    Article  PubMed  CAS  Google Scholar 

  37. Kelley MC,Gupta RK,Hsueh EC, et al.:Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma. J Clin Oncol 2001, 19:1176–1182.

    PubMed  CAS  Google Scholar 

  38. Litvak DA,Gupta RK,Yee R, et al.:Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors. J Am Coll Surg 2004, 198:27–35.

    Article  PubMed  Google Scholar 

  39. Chung MH,Gupta RK,Essner R, et al.:Serum TA90 immune complex assay can predict outcome after resection of thick (> or =4 mm) primary melanoma and sentinel lymphadenectomy. Ann Surg Oncol 2002, 9:120–126.

    PubMed  Google Scholar 

  40. DuClos TW: Function of C-reactive protein. Ann Med 2000, 32:274–278.

    CAS  Google Scholar 

  41. Mahmoud FA,Rivera NI: The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002, 4:250–255.

    Article  PubMed  Google Scholar 

  42. Tartour E,Dorval T,Mosseri V, et al.:Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994, 69:911–913.

    PubMed  CAS  Google Scholar 

  43. Ziegler A,Zangemeister-Wittke U,Stahel RA: Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev 2002, 28:255–271.

    Article  PubMed  CAS  Google Scholar 

  44. Goydos JS,Mann B,Kim HJ, et al.:Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005, 200:362–370.

    Article  PubMed  Google Scholar 

  45. Palmieri G,Ascierto PA,Cossu A, et al.:Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. Melanoma Res 2003, 13:167–170.

    Article  PubMed  CAS  Google Scholar 

  46. Herbst RA,Mommert S,Casper U, et al.:11q23 allelic loss is associated with regional lymph node metastasis in melanoma. Clin Cancer Res 2000, 6:3222–3227.

    PubMed  CAS  Google Scholar 

  47. Herbst RA,Weiss J,Ehnis A, et al.:Loss of heterozygosity for 10q22-10qter in malignant melanoma progression. Cancer Res 1994, 54:3111–3114.

    PubMed  CAS  Google Scholar 

  48. Fujiwara Y,Chi DD,Wang H, et al.:Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res 1999, 59:1567–1571.

    PubMed  CAS  Google Scholar 

  49. Taback B,Fujiwara Y,Wang HJ, et al.:Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res 2001, 61:5723–5726. Good review of microsatellite markers and their uses in clinical medicine. Good technique section and excellent discussion.

    PubMed  CAS  Google Scholar 

  50. Taback B,O’Day SJ,Boasberg PD, et al.:Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J Natl Cancer Inst 2004, 96:152–156.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Cancer Institute of New Jersey, 195 Little Albany Street, 08901, New Brunswick, NJ, USA

    Nicole Kounalakis MD & James S. Goydos MD

Authors
  1. Nicole Kounalakis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James S. Goydos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kounalakis, N., Goydos, J.S. Tumor cell and circulating markers in melanoma: Diagnosis, prognosis, and management. Curr Oncol Rep 7, 377–382 (2005). https://doi.org/10.1007/s11912-005-0065-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-005-0065-2

Keywords

Search

Navigation